Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $264,110

• Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold 3,500 common shares on Sep. 8, 2026 at USD 75.46.
• Sale followed the exercise of 3,500 non-qualified stock options at USD 7.8 per share.
• Direct common stock holdings fell to 153,902 shares.
• Non-qualified stock options held declined to 26,886, with an exercise price of USD 7.8.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000092), on September 08, 2026, and is solely responsible for the information contained therein.